Actavis gets FDA approval for Trimipramine Maleate capsules

By Elaine Rigoli

Tampa, Fla., Sept. 22 - Actavis U.S. said it has received approval from the Food and Drug Administration to market Trimipramine Maleate capsules and will start distribution immediately.

The Cranford, N.J.-based pharmaceutical company said Trimipramine Maleate capsules, the generic equivalent of Odyssey Pharmaceuticals' Surmontil capsules, are available in 25 mg, 50 mg and 100 mg strengths.

Trimipramine Maleate is indicated for the relief of symptoms of depression.

Annual brand sales of Trimipramine Maleate capsules in the United States were about $4.2 million for the 12 months ended June 2006 according to IMS Health data.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.